Jane Street’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-113,150
Closed -$344K 11075
2024
Q4
$344K Sell
113,150
-455,504
-80% -$1.98M ﹤0.01% 7509
2024
Q3
$2.95M Buy
568,654
+404,741
+247% +$2.01M ﹤0.01% 3742
2024
Q2
$421K Buy
163,913
+24,012
+17% +$82K ﹤0.01% 7292
2024
Q1
$688K Buy
139,901
+82,716
+145% +$490K ﹤0.01% 6110
2023
Q4
$503K Sell
57,185
-89,797
-61% -$736K ﹤0.01% 6744
2023
Q3
$1.69M Buy
146,982
+34,995
+31% +$673K ﹤0.01% 4324
2023
Q2
$2.83M Sell
111,987
-162,812
-59% -$5.07M ﹤0.01% 3598
2023
Q1
$8.85M Buy
274,799
+249,255
+976% +$7.77M ﹤0.01% 1768
2022
Q4
$472K Sell
25,544
-221,521
-90% -$5.07M ﹤0.01% 6232
2022
Q3
$6.67M Buy
247,065
+206,702
+512% +$4.19M ﹤0.01% 2188
2022
Q2
$558K Sell
40,363
-59,973
-60% -$923K ﹤0.01% 6530
2022
Q1
$1.96M Buy
100,336
+70,636
+238% +$1.07M ﹤0.01% 4807
2021
Q4
$485K Sell
29,700
-6,261
-17% -$104K ﹤0.01% 7328
2021
Q3
$1M Buy
+35,961
New +$1.03M ﹤0.01% 5901
2021
Q1
Sell
-36,855
Closed -$1.02M 9688
2020
Q4
$1.04M Buy
36,855
+12,823
+53% +$332K ﹤0.01% 4587
2020
Q3
$605K Buy
+24,032
New +$630K ﹤0.01% 4860
2019
Q2
Sell
-20,029
Closed -$316K 5888
2019
Q1
$316K Buy
20,029
+6,441
+47% +$112K ﹤0.01% 4198
2018
Q4
$274K Buy
+13,588
New +$299K ﹤0.01% 4173
2018
Q1
Sell
-19,172
Closed -$685K 5534
2017
Q4
$685K Buy
+19,172
New +$551K ﹤0.01% 2803

Other funds holding RVNC

Jane Street's RVNC Position: Q1 2025 in Review

Jane Street sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 113,150 shares — an estimated $344K sold.

Jane Street first reported a position in RVNC in Q4 2017 and held it in 19 quarters. The position peaked at $8.85M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Jane Street reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Jane Street sold 113,150 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $344K.
  • Jane Street first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 19 quarters.
  • Jane Street's Revance Therapeutics, Inc. position peaked at $8.85M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.